These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18941464)

  • 1. Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells.
    Sun ZJ; Wang Y; Cai Z; Chen PP; Tong XJ; Xie D
    Br J Cancer; 2008 Nov; 99(10):1656-67. PubMed ID: 18941464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis.
    Huang YT; Lan Q; Lorusso G; Duffey N; Rüegg C
    Oncotarget; 2017 Feb; 8(6):9200-9215. PubMed ID: 27911269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of cysteine-rich protein 61 in the epidermal growth factor-induced migration of human anaplastic thyroid cancer cells.
    Chin LH; Hsu SP; Zhong WB; Liang YC
    Mol Carcinog; 2016 May; 55(5):622-32. PubMed ID: 25773758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response.
    Feng P; Wang B; Ren EC
    Int J Biochem Cell Biol; 2008; 40(1):98-109. PubMed ID: 17698398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA target for MACC1 and CYR61 to inhibit tumor growth in mice with colorectal cancer.
    Wang G; Gu J; Gao Y
    Tumour Biol; 2016 Oct; 37(10):13983-13993. PubMed ID: 27492459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
    Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
    Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis.
    Fromigue O; Hamidouche Z; Vaudin P; Lecanda F; Patino A; Barbry P; Mari B; Marie PJ
    J Bone Miner Res; 2011 Jul; 26(7):1533-42. PubMed ID: 21312266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of proliferation, invasion, and migration of prostate cancer cells by downregulating elongation factor-1alpha expression.
    Zhu G; Yan W; He HC; Bi XC; Han ZD; Dai QS; Ye YK; Liang YX; Wang J; Zhong W
    Mol Med; 2009; 15(11-12):363-70. PubMed ID: 19707524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyr61 as mediator of Src signaling in triple negative breast cancer cells.
    Sánchez-Bailón MP; Calcabrini A; Mayoral-Varo V; Molinari A; Wagner KU; Losada JP; Ciordia S; Albar JP; Martín-Pérez J
    Oncotarget; 2015 May; 6(15):13520-38. PubMed ID: 25980494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Snail/FOXK1/Cyr61 Signaling Axis Regulates the Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.
    Huang X; Xiang L; Li Y; Zhao Y; Zhu H; Xiao Y; Liu M; Wu X; Wang Z; Jiang P; Qing H; Zhang Q; Liu G; Zhang W; Li A; Chen Y; Liu S; Wang J
    Cell Physiol Biochem; 2018; 47(2):590-603. PubMed ID: 29794466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status.
    Lv H; Fan E; Sun S; Ma X; Zhang X; Han DM; Cong YS
    J Cell Biochem; 2009 Mar; 106(4):738-44. PubMed ID: 19180570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
    Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
    Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rβ-dependent EMT-like process.
    Habel N; Stefanovska B; Carène D; Patiño-Garcia A; Lecanda F; Fromigué O
    BMC Cancer; 2019 Jan; 19(1):62. PubMed ID: 30642298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyr61/CCN1 affects the integrin-mediated migration of prostate cancer cells (PC-3) in vitro.
    Schmitz P; Gerber U; Jüngel E; Schütze N; Blaheta R; Bendas G
    Int J Clin Pharmacol Ther; 2013 Jan; 51(1):47-50. PubMed ID: 23259998
    [No Abstract]   [Full Text] [Related]  

  • 15. Silencing of BACH1 inhibits invasion and migration of prostate cancer cells by altering metastasis-related gene expression.
    Shajari N; Davudian S; Kazemi T; Mansoori B; Salehi S; Khaze Shahgoli V; Shanehbandi D; Mohammadi A; Duijf PHG; Baradaran B
    Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1495-1504. PubMed ID: 28889753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The matrix protein CCN1/CYR61 is required for α(V)β5-mediated cancer cell migration.
    Jandova J; Beyer TE; Meuillet EJ; Watts GS
    Cell Biochem Funct; 2012 Dec; 30(8):687-95. PubMed ID: 22692860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening and identification of significant genes related to tumor metastasis and PSMA in prostate cancer using microarray analysis.
    Xu L; Wang Z; Li XF; He X; Guan LL; Tuo JL; Wang Y; Luo Y; Zhong HL; Qiu SP; Cao KY
    Oncol Rep; 2013 Oct; 30(4):1920-8. PubMed ID: 23917490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-metastatic functions of Notch signaling is mediated by CYR61 in breast cells.
    Ilhan M; Kucukkose C; Efe E; Gunyuz ZE; Firatligil B; Dogan H; Ozuysal M; Yalcin-Ozuysal O
    Eur J Cell Biol; 2020 Apr; 99(2-3):151070. PubMed ID: 32005345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
    Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.
    Marra M; Santini D; Meo G; Vincenzi B; Zappavigna S; Baldi A; Rosolowski M; Tonini G; Loeffler M; Lupu R; Addeo SR; Abbruzzese A; Budillon A; Caraglia M
    Int J Cancer; 2009 Nov; 125(9):2004-13. PubMed ID: 19530242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.